Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Am J Addict. 2020 Jun 23:10.1111/ajad.13069. doi: 10.1111/ajad.13069

Method for Successfully Inducting Individuals who use Illicit Fentanyl onto Buprenorphine/naloxone

Denis Antoine 1, Andrew S Huhn 1, Eric C Strain 1, Gavin Turner 1, Jasmyne Jardot 1, Alexis S Hammond 1, Kelly E Dunn 1
PMCID: PMC7755703  NIHMSID: NIHMS1616487  PMID: 32572978

Abstract

Background and Objectives:

Individuals exposed to fentanyl are at risk of precipitated withdrawal using typical buprenorphine/naloxone induction procedures.

Methods:

This case series describes buprenorphine/naloxone inductions of four individuals who tested positive for fentanyl.

Results:

Buprenorphine-precipitated withdrawal was observed in two individuals who completed a conventional buprenorphine/naloxone induction strategy. Two more individuals completed a revised buprenorphine/naloxone induction strategy that did not precipitate withdrawal.

Discussion and Conclusion:

Using multiple 2mg doses of buprenorphine/naloxone in patients already in mild/moderate withdrawal improved outcomes.

Scientific Significance:

Persons who use illicit fentanyl might be less likely to experience precipitated withdrawal from this revised buprenorphine/naloxone induction strategy.

Keywords: Fentanyl, Opioid, Buprenorphine, Induction, Withdrawal, Addiction, Precipitated

Introduction

The landscape of illicit opioid use in the U.S. has shifted from heroin to fentanyl1–3, a high potency mu opioid agonist with high affinity at the mu opioid receptor. Fentanyl has a similar binding affinity and excretion half-life as morphine4, yet is significantly more potent than other opioids. In addition, fentanyl is highly lipophilic5,6 and is actively transported across the blood-brain-barrier into cerebrospinal fluid7, thus conferring rapid subjective and analgesic effects upon intravenous administration8. This high lipophilicity also causes fentanyl to be redistributed into adipocytes9, which may result in protracted excretion patterns following repeated fentanyl exposure. The majority of information available regarding fentanyl pharmacokinetic and dynamic properties pertains to commercially produced versions of fentanyl (which are generally transdermal) – we can find no literature that outlines the pharmacokinetic and dynamic characteristics of fentanyl that is acquired through adulterated heroin products, which is likely a far larger dose than what would be medically administered. Anecdotal reports from the field indicate persons with frequent heroin exposure can test positive for fentanyl for extended periods of time in urine samples, and our study has observed that individuals who abstain from heroin for 24–48 hours can present with a fentanyl-positive urinalysis and experience buprenorphine-precipitated withdrawal. This time course suggests that fentanyl may be conferring extended mu-opioid receptor agonist effects. The only peer-reviewed paper on this topic is a qualitative survey study conducted among persons using illicit heroin (N=63) that found several individuals who reported treating themselves with buprenorphine had precipitated withdrawal more than 72 hours after their last use2. This was also reported in a commentary that discussed unpublished reports on buprenorphine induction challenges from the field10.

Buprenorphine is an established treatment for opioid use disorder (OUD), and offered in OUD treatment facilities at a higher rate than methadone and naltrexone11–12. Buprenorphine is a competitive partial agonist with high affinity for the mu opioid receptor and because it readily displaces other mu agonists, including fentany13, a cautious induction procedure is required to prevent withdrawal precipitation. A buprenorphine/naloxone induction protocol that was outlined in an early publication14 has now become a fairly routine process whereby individuals receive a 4mg sublingual (SL) dose of buprenorphine/naloxone once they demonstrate mild opioid withdrawal, are monitored for precipitated withdrawal, and receive a second 4mg SL dose approximately three hours later14. This procedure has been successful for persons with OUD who use heroin or prescription opioids15; however, buprenorphine/naloxone induction now presents a significant clinical challenge in patients exposed to fentanyl, namely an increased risk of precipitated withdrawal that is likely related to its aforementioned unique pharmacokinetic profile relative to other opioids. Other case series have demonstrated that rapid microdosing of buprenorphine, even in the presence of other opioid agonists, can be successful in quickly inducting persons with OUD onto buprenorphine16–17.

This case series outlines the experience of four consecutive individuals with recent fentanyl exposure who were inducted onto buprenorphine/naloxone as part of a randomized controlled trial of a sleep medication during opioid tapering. Buprenorphine/naloxone induction was not a main outcome of the trial and thought to be a routine and low-risk procedure. It was observed that the standard induction protocol precipitated substantial opioid withdrawal in two individuals (#1, #2), so modifications were made to the dose and inter-dose intervals of buprenorphine/naloxone administration. This revised procedure allowed the two subsequent individuals (#3, #4) to be comfortably inducted onto buprenorphine/naloxone with no evidence of precipitated withdrawal. Given the large infiltration of fentanyl in the U.S. and the reliance on buprenorphine/naloxone as a primary form of medication therapy, this revised procedure may be of significant value to providers.

Case Presentations

Overview

All individuals were instructed to abstain from opioids for >24 hours and to present for buprenorphine induction in mild-moderate levels of withdrawal. Participants were tested for fentanyl using Rapid Response™ qualitative fentanyl dipsticks with a 20ng/mL cutoff. All buprenorphine/naloxone doses were administered in SL tablets to reach a target dose of 8mg. Figure 1 displays individual cumulative buprenorphine/naloxone dosing and opioid withdrawal ratings as collected by the observer-rated Clinical Opiate Withdrawal Scale (COWS)18–19, and Table 1 provides relevant medical information.

Figure 1. Buprenorphine Cumulative Dose and Associated Opioid Withdrawal Severity.

Figure 1.

Figure 1A presents results of participants 1 and 2 and shows evidence of precipitated opioid withdrawal following completion of the standard buprenorphine/naloxone induction procedure. Figure 1B shows results of participants 3 and 4, who had no evidence of precipitated withdrawal following a revised induction buprenorphine/naloxone induction procedure. Arrows indicate time of buprenorphine/naloxone sublingual dosing and gray bars present cumulative buprenorphine/naloxone dose over time in milligrams (mg) as indicated by the right Y-axis. Lines represent Clinical Opiate Withdrawal Scale (COWS) ratings, an observer-rated measure of opioid withdrawal (range of 0–48), which are plotted on the left Y-axis. Dashed lines indicate COWS thresholds of mild withdrawal (≥5), moderate withdrawal (≥12) and severe withdrawal (≥25), with values in the mild range in black and post-buprenorphine values in the moderate-severe range in red. X-axes represent time in minutes, with initial buprenorphine/naloxone dosing set at time 0. Note that participants had ratings collected at different timepoints, so data are truncated to reflect the final COWS score after the 8mg dose had been reached. As can be seen, Participants 1 and 2 received buprenorphine while still in the mild withdrawal range and had several post-buprenorphine dosing values within the moderate or severe ranges. In contrast, Participants 3 and 4 did not receive buprenorphine until they had moved into moderate withdrawal; Participant 3 had two instances of moderate withdrawal post-buprenorphine dosing and Participant 4 remained in mild withdrawal for the duration.

Table 1.

Patient Characteristics

Patient Number Age (years) Race Gender BMI Category Previous 30 days usea Last Opioid Use (Hours) SUD history Medical History
1 41–55 Caucasian Man Overweight 4–5 fentanyl capsules per day, IN. 24 5 years heroin/fentanyl use, IN; 20 years prescription opioid misuse No clinically significant issues
2 26–40 Non-Caucasian Woman Obese 2–3 capsules of heroin/ fentanyl per day, IV. 20 3 years heroin/fentanyl, IN and IV Chronic pain, mood disorders
3 18–25 Caucasian Man Overweight 3–4 capsules of fentanyl/ heroin per day, IN. 48 2 years heroin/fentanyl use, IN; 1 year cocaine use No clinically significant issues
4 26–40 Caucasian Man Normal 1 capsule of fentanyl/ heroin per day, IN. 48 4 years heroin/fentanyl IN; 3 years cocaine use No clinically significant issues

Data are presented in categories to protect participant confidentiality. All patients met criteria for the severe form of OUD

BMI=body mass index, SUD=substance use disorder, IN=intranasal, IV=intravenous

Cases

Participant characteristics can be found in Table 1, and response to buprenorphine/naloxone can be found in Figure 1.

Participant 1 was diagnosed with severe OUD and had been using heroin/fentanyl for five years and prescription opioids for 20 years. He reported using 4–5 capsules of fentanyl each day via the intranasal route in the 30 days prior to induction (in the region this study was conducted, heroin/fentanyl is sold in “capsules”, which are illicit and do not represent a commercially available product). His qualitative urine tests were positive for fentanyl, morphine, and cocaine on admission and he self-reported his last opioid use was 24 hours prior. The induction followed standard procedures, beginning with a 4mg buprenorphine/naloxone dose following COWS rating ≥9 and a second 4mg buprenorphine/naloxone dose after 180 minutes. COWS scores increased to a moderate range (19) after the first dose and continued to increase after the 180- minute dose. It was concluded that the buprenorphine/naloxone dosing strategy had precipitated acute opioid withdrawal.

Participant 2 was diagnosed with severe OUD and had been using heroin/fentanyl for 3 years. She reported using approximately 2–3 capsules of heroin intravenously each day in the 30 days prior to induction and her last self-reported use was approximately 20 hours prior. Importantly, she did not know she was exposed to fentanyl until her qualitative urine results revealed she was positive for fentanyl and benzodiazepines. The induction followed standard protocol and began with a 4mg dose of buprenorphine/naloxone following COWS ≥9. Forty-five minutes after dosing, her COWS ratings abruptly increased to 35 (severe) and remained at this level for one hour, before dropping to 29, and finally to 19 approximately 180 minutes after dosing. The participant was then given the second 4mg buprenorphine/naloxone dose with continuation of severe withdrawal symptoms. It was concluded that buprenorphine/naloxone precipitated acute opioid withdrawal.

Participant 3 was diagnosed with severe OUD and had been using heroin/fentanyl for two years and cocaine for one year. He reported using 3–4 capsules of a mixture of fentanyl and heroin via the intranasal route on a daily basis in the prior 30 days. On admission, his qualitative urine tests were positive for cocaine and fentanyl and his last self-reported opioid use was 48 hours prior. This participant’s induction was delayed until his COWS score was 13, at which time he received a 2mg dose of buprenorphine/naloxone. He was monitored for evidence of precipitated withdrawal and received additional 2mg doses at 100min, 220 min, and 368 min. Withdrawal symptoms were observed to be well-managed throughout the day, with COWS scores ranging from 3–14. It was concluded that buprenorphine/naloxone did not precipitate withdrawal.

Participant 4 was diagnosed with severe OUD and had been using a mixture of fentanyl and heroin for four years and cocaine for three years. He reported using 1 capsule per day of heroin/fentanyl via the intranasal route in the 30 days prior to induction. On admission, his qualitative urine tests were positive for morphine, fentanyl, and cocaine and his last self-reported opioid use was 48 hours prior. Induction did not begin until his COWS was 13, at which time he received a 2mg dose of buprenorphine/naloxone. He was monitored for evidence of precipitated withdrawal and received additional 2mg doses at 85 min, 160 min, and 190 min. His withdrawal remained well-managed throughout the day, with COWS ranging from 6–10. It was concluded that buprenorphine/naloxone did not precipitate withdrawal.

Discussion

This case series identifies real-world methods that should be considered for inducting persons with recent fentanyl exposure onto buprenorphine/naloxone. Initial attempts to utilize a conventional induction procedure precipitated moderate-to-severe withdrawal in individuals presenting with fentanyl-positive urine samples. A revised procedure that required higher initial withdrawal (COWS ≥12), administered smaller (2mg, SL) doses of buprenorphine/naloxone20, and modified the inter-dose interval to 60–90 minutes was more effective in keeping COWS ratings low and well-managed relative to the conventional induction procedure. The rationale for these adjustments was the pharmacokinetic profile of buprenorphine; the 60–90-minute inter-dose interval appears to allow for buprenorphine to establish a partial agonist effect without precipitating withdrawal.

It is notable that individuals presenting with fentanyl positive urine samples were able to abstain from opioids for a longer period (~48 hours) without going into severe withdrawal; while this might be more challenging for participants to accomplish it appears necessary to prevent buprenorphine-precipitated withdrawal and ensure successful induction. Additionally, self-reports of heroin use conflicted with negative qualitative urine toxicology screens for morphine and associated metabolites and unexpected fentanyl-positive tests. These issues suggest that relying on self-report of recent heroin use to initiate buprenorphine/naloxone induction may be problematic. Quantitative fentanyl testing conducted prior to induction may also prove helpful to guide induction decisions, since the conventional process of sending the quantitative tests to an outside lab prevents the receipt of results in a timely enough manner to guide immediate clinical decisions. An alternative to qualitative testing would be to integrate on-site quantitative testing or semi-quantitative test strips that use an established fentanyl cut-off (i.e. persons under a certain fentanyl level may be at lower risk for precipitated withdrawal) for more precise fentanyl detection in a more rapid time period.

Buprenorphine/naloxone absorption and metabolization were not quantified in this study but could affect COWS scores and/or contribute to precipitated withdrawal in persons who use fentanyl. Also, qualitative testing could be cross-reactive for fentanyl and the metabolite norfentanyl, and it is unclear whether participants were also exposed to fentanyl analogues that are increasingly used to cut heroin. Further research is needed to elucidate the pharmacokinetics of fentanyl elimination, especially in the context of buprenorphine induction.

Our use of 2mg doses in the revised procedure are consistent with prior evidence that co-administering extremely low doses of buprenorphine (e.g. 0.2mg) following full agonist use can be effective in transitioning OUD individuals onto buprenorphine/naloxone maintenance16–17, and our use of the commercially available 2mg dose will allow this procedure to be easily adopted by other programs. Further research on this topic is critical in light of the rising rates of fentanyl-adulterated heroin and/or individuals presenting with only fentanyl use. Such research can support buprenorphine/naloxone inductions from other opioid agonists (e.g., methadone) that have also proven difficult and would increase medication treatment flexibility for individuals with OUD.

Acknowledgments

Financial Acknowledgements: The work described in this manuscript was funded by the National Institute on Drug Abuse, Bethesda, MD: NIDA UG3DA048734 (Huhn).

Footnotes

Consent: All participants consented to take part in this study. This study was reviewed and approved by the Johns Hopkins University School of Medicine Institutional Review Board.

Declaration of Interests: ASHu receives research funding from Ashley Addiction Treatment through his university. In the past 3 years, KED has served as a consultant for Beckley Canopy Therapeutics, Canopy Therapuetics, and Grünenthal. ECS has served on advisory boards, received grant funding from, and/or consulted for Alkermes, Analgesic Solutions, Caron, Indivior Pharmaceuticals, Innocoll Pharmaceuticals, The Oak Group/VitalHub, UpToDate, Otsuka Pharmaceutical Development and Commercialization, and Pinney Associates. He has received honoraria from the World Health Organization, and is currently collaborating with Innovative Health Solutions. All other authors report no financial disclosures.

References

  • 1.Ochalek TA, Parker MA, Higgins ST, Sigmon SC. Fentanyl exposure among patients seeking opioid treatment. J Subst Abuse Treat, 2019;96:23–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Silverstein SM, Daniulaityte R, Martins SS, Miller SC, Carlson RG. ‘Everything is not right anymore’: Buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy, 2019;74:76–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gryczynski J, Nichols H, Schwartz RP, Mitchell SG, Hill P, Wireman K. Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder. Drug Alcohol Depend, 2019;204:107515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Villiger JW, Ray LJ, & Taylor KM (1983). Characteristics of [3H] fentanyl binding to the opiate receptor. Neuropharmacology, 22(4), 447–452. [DOI] [PubMed] [Google Scholar]
  • 5.Roy SD, & Flynn GL (1988). Solubility and related physicochemical properties of narcotic analgesics. Pharmaceutical Research, 5(9), 580–586. [DOI] [PubMed] [Google Scholar]
  • 6.Pöyhiä R, & Seppälä T (1994). Liposolubility and protein binding of oxycodone in vitro. Pharmacology & Toxicology, 74(1), 23–27. [DOI] [PubMed] [Google Scholar]
  • 7.Henthorn TK, Liu Y, Mahapatro M, & Ng KY (1999). Active transport of fentanyl by the blood-brain barrier. Journal of Pharmacology and Experimental Therapeutics, 289(2), 1084–1089. [PubMed] [Google Scholar]
  • 8.Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev, 2019;106:49–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Hug CC, & Murphy MR (1981). Tissue redistribution of fentanyl and termination of its effects in rats. Anesthesiology, 55(4), 369–375. [DOI] [PubMed] [Google Scholar]
  • 10.Bisaga A What should clinicians do as fentanyl replaces heroin? Addiction, 2019;114:782–3. [DOI] [PubMed] [Google Scholar]
  • 11.Alderks CE. Trends in the Use of Methadone, Buprenorphine, and Extended-Release Naltrexone at Substance Abuse Treatment Facilities: 2003–2015 (Update) The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2017. [PubMed] [Google Scholar]
  • 12.Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities. Health Aff, 2019;38:14–23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine. The significance of receptor binding. Br J Anaesth, 1985;57:192–6. [DOI] [PubMed] [Google Scholar]
  • 14.Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend, 2003;70:S59–77. [DOI] [PubMed] [Google Scholar]
  • 15.Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat, 2010;39:51–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid Micro‐Induction of Buprenorphine/Naloxone for Opioid Use Disorder in an Inpatient Setting: A Case Series. Am J Addict, 2019;28:262–5. [DOI] [PubMed] [Google Scholar]
  • 17.Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil, 2016;7:99–105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend, 2009;105:154–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs, 2003;35:253–9. [DOI] [PubMed] [Google Scholar]
  • 20.Rosado J, Walsh SL, Bigelow GE, Strain EC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend, 2007:261–9. 10.1016/j.drugalcdep.2007.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES